(Reuters) – Eisai and Biogen (NASDAQ:) have launched their Alzheimer’s treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday.
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer’s treatment proven to alter the course of the fatal, brain-wasting disease.
The drug will first be launched in the private market at 2,508 yuan ($345.04) for a 200 mg vial, the companies said in a statement.
Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer.
China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
More convenient Alzheimer’s blood tests expected to be ready by 2025 could help Eisai reach a bigger share of China’s estimated 17 million people with early-stage disease, a company spokesperson had told Reuters after approval in China.
($1 = 7.2688 )
https://i-invdn-com.investing.com/news/Biogen_800x533_L_1629564936.jpg
Source link
Reuters
